Publications by authors named "Jeff Blaney"

Claim this Profile
P
Publisher Correction: Deep-learning-based virtual screening of antibacterial compounds.
Gabriele Scalia, Steven T Rutherford, Ziqing Lu, Kerry R Buchholz, Nicholas Skelton, Jeff Blaney

Nat Biotechnol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep-learning-based virtual screening of antibacterial compounds.
Gabriele Scalia, Steven T Rutherford, Ziqing Lu, Kerry R Buchholz, Nicholas Skelton, Jeff Blaney

Nat Biotechnol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking drug design in the artificial intelligence era.
Petra Schneider, W Patrick Walters, Alleyn T Plowright, Norman Sieroka, Jennifer Listgarten, Jeff Blaney

Nat Rev Drug Discov· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Learning Medicinal Chemistry Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Rules from Cross-Company Matched Molecular Pairs Analysis (MMPA).
Christian Kramer, Attilla Ting, Hao Zheng, Jérôme Hert, Torsten Schindler, Jeff Blaney

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of the First wwPDB/CCDC/D3R Ligand Validation Workshop.
Paul D Adams, Kathleen Aertgeerts, Cary Bauer, Jeffrey A Bell, Helen M Berman, Jeff M Blaney

Structure· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors.
Daniel J Burdick, Shumei Wang, Christopher Heise, Borlan Pan, Jake Drummond, Jeff Blaney

Bioorg Med Chem Lett· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrated suite of modeling tools that empower scientists in structure- and property-based drug design.
Jianwen A Feng, Ignacio Aliagas, Philippe Bergeron, Jeff M Blaney, Erin K Bradley

J Comput Aided Mol Des· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
Emily J Hanan, Anne van Abbema, Kathy Barrett, Wade S Blair, Jeff Blaney

J Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A very short history of structure-based design: how did we get here and where do we need to go?
Jeff Blaney

J Comput Aided Mol Des· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
Sean G Buchanan, Jorg Hendle, Patrick S Lee, Christopher R Smith, Pierre-Yves Bounaud, Jeff M Blaney

Mol Cancer Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors.
Stephen S Antonysamy, Brandon Aubol, Jeff Blaney, Michelle F Browner, Anthony M Giannetti

Bioorg Med Chem Lett· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis